Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Goldenwell Biotech (GWLL) Return on Sales (2020 - 2025)

Goldenwell Biotech (GWLL) has disclosed Return on Sales for 6 consecutive years, with 142.3% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Sales rose 8937.0% year-over-year to 142.3%, compared with a TTM value of 142.3% through Sep 2025, up 8937.0%, and an annual FY2024 reading of 946.03%, down 88211.0% over the prior year.
  • Return on Sales was 142.3% for Q3 2025 at Goldenwell Biotech, down from 33.56% in the prior quarter.
  • Across five years, Return on Sales topped out at 223.93% in Q4 2022 and bottomed at 10172.0% in Q1 2021.
  • Average Return on Sales over 5 years is 621.96%, with a median of 84.1% recorded in 2022.
  • The sharpest move saw Return on Sales soared 1008790bps in 2022, then crashed -36345bps in 2024.
  • Year by year, Return on Sales stood at 10.97% in 2021, then soared by 2142bps to 223.93% in 2022, then tumbled by -136bps to 80.0% in 2023, then plummeted by -454bps to 443.45% in 2024, then surged by 68bps to 142.3% in 2025.
  • Business Quant data shows Return on Sales for GWLL at 142.3% in Q3 2025, 33.56% in Q2 2025, and 298.54% in Q1 2025.